Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.

Dehbi, H-M., Mallick, U., Wadsley, J. et al. (3 more authors) (2019) Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial. Lancet Diabetes and Endocrinology, 7 (1). pp. 44-51. ISSN 2213-8587

Abstract

Metadata

Authors/Creators:
  • Dehbi, H-M.
  • Mallick, U.
  • Wadsley, J.
  • Newbold, K.
  • Harmer, C..
  • Hackshaw, A.
Copyright, Publisher and Additional Information: © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/
Dates:
  • Accepted: 18 October 2018
  • Published (online): 27 November 2018
  • Published: 1 January 2019
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 18 Mar 2019 14:49
Last Modified: 18 Mar 2019 14:49
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: https://doi.org/10.1016/S2213-8587(18)30306-1
Related URLs:

Share / Export

Statistics